Chronic obstructive pulmonary disease
Conditions
Interventions
Observation group:None
Sponsors
The Second Hospital of Shanxi Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Patients with COPD and lung cancer: no age limit, no gender limit; Patients with suspected or confirmed diagnosis of COPD (pulmonary function tests are required for the diagnosis, FEV1/FVC <70% after expansion) and the diagnosis of primary lung cancer is confirmed by histopathological examinations such as surgical resection of specimens, bronchoscopic fine needle aspiration or percutaneous lung biopsy tissue; Subjects voluntarily participate in this clinical trial and sign the informed consent form. The investigator judges that the subject's compliance meets the requirements of this study. 2. Patients with COPD and sleep apnea (OSA): patients over 18 years old, regardless of race or gender; Patients diagnosed with COPD (dilated FEV1/FVC <70%) by pulmonary function tests in our hospital, and patients diagnosed with OSA by overnight monitoring by polysomnography (Embla N7000 multi-conductive series made in the United States); The patient voluntarily signed the informed consent form and was able to cooperate with the follow-up according to his requirements. 3. Patients with COPD and pulmonary interstitial fibrosis: COPD combined with pulmonary interstitial fibrosis (determined by experienced respiratory specialists and imaging specialists). 4. Patients with acute exacerbation of COPD complicated with anxiety and depression: confirmed chronic obstructive pulmonary disease (COPD): patients diagnosed with COPD according to the criteria of the Global Initiative (GOLD) or the American Thoracic Society (ATS). between 18 and 80 years old; Able to understand the content of the study and sign the informed consent form: Participants should have sufficient cognitive ability to understand the purpose and process of the study, and participate voluntarily. Able to cooperate with the assessment and follow-up required to complete the study: including pulmonary function tests, psychological assessments, questionnaires, etc.
Exclusion criteria
Exclusion criteria: 1. Patients with COPD and lung cancer: severe mental or neurological disorders that affect informed consent and/or adverse reaction expression or observation; metastatic lung cancer; Inability to complete the first questionnaire and perform pulmonary function tests; Subjects who are participating in other drug clinical trials or interventional studies. 2. Patients with COPD and sleep apnea (OSA): severe psychiatric or neurological disorders that affect informed consent and/or adverse reaction expression or observation; Inability to complete the first questionnaire and perform pulmonary function tests; Subjects who are participating in other drug clinical trials or interventional studies. 3. Patients with COPD and pulmonary interstitial fibrosis: pulmonary interstitial fibrosis associated with connective tissue disease or vasculitis; Related pulmonary interstitial fibrosis with tumor and treated with radiotherapy or targeted therapy or immunotherapy, amiodarone, bleomycin, etc.; interstitial pulmonary fibrosis caused by occupational dust; Sarcoidosis and other pulmonary interstitial fibrosis of clear etiology. 4. Patients with acute exacerbation of COPD combined with anxiety and depression: other serious cardiopulmonary diseases: such as severe heart disease, pulmonary fibrosis, etc.; Patients with a history of psychiatric illness, and patients with a history of other serious psychiatric disorders, patients who are receiving anti-anxiety or antidepressant therapy; Patients who are using medications that may cause psychiatric symptoms; Inability to cooperate with the assessment and follow-up required to complete the study: including inability to understand the content of the study, inability to participate in the assessment and follow-up on time, etc.; Other factors that may affect the results of the study: such as alcoholism, drug abuse, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| All-cause mortality of different COPD comorbidities during follow-up; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes of lung function and quality of life in patients with different COPD complications at the end of follow-up;Describe the current status of drug treatment in patients with different COPD comorbidities in the real world;To compare the differences of management models and guidelines for COPD complications in the real world;Risk assessment system of different COPD complications;Average direct medical costs per year for COPD patients during follow-up;Cost/effectiveness analysis of different treatment options; | — |
Countries
China
Contacts
Public ContactZhao Hui
The Second Hospital of Shanxi Medical University
Outcome results
None listed